Backes, C. H., Donovan, J. L., & Slaughter, J. L. (2019). Catheter-based closure of the patent ductus arteriosus in preterm infants: considerations in the design of a randomized trial. *Journal of Perinatology*, 39(11), 1437-1438. <https://doi.org/10.1038/s41372-019-0484-9>

Peer reviewed version

Link to published version (if available):
[10.1038/s41372-019-0484-9](https://doi.org/10.1038/s41372-019-0484-9)

[Link to publication record in Explore Bristol Research](#)
PDF-document

This is the author accepted manuscript (AAM). The final published version (version of record) is available online via Springer Nature at <https://www.nature.com/articles/s41372-019-0484-9> . Please refer to any applicable terms of use of the publisher.

University of Bristol - Explore Bristol Research

General rights

This document is made available in accordance with publisher policies. Please cite only the published version using the reference above. Full terms of use are available:
<http://www.bristol.ac.uk/red/research-policy/pure/user-guides/ebr-terms/>

Catheter-Based Closure of the Patent Ductus Arteriosus in Preterm Infants: Considerations in the Design of a Randomized Trial

Carl H. Backes, MD^{1,2,3,4}; Jenny L. Donovan, PhD⁵; Jonathan L Slaughter, MD,
MPH,^{1,3,4,7}

¹ Center for Perinatal Research, Nationwide Children's Hospital, Columbus, OH

² The Heart Center at Nationwide Children's Hospital, Columbus, OH

³ Department of Pediatrics, The Ohio State University Wexner Medical Center,
Columbus, OH

⁴ Division of Neonatology, Nationwide Children's Hospital, Columbus, OH

⁵ Population Health Sciences, University of Bristol, Canynge Hall, Whiteladies Road,
Bristol, United Kingdom

⁷ Division of Epidemiology, The Ohio State University College of Public Health,
Columbus, OH

Keywords: Infant, Patent Ductus Arteriosus, Percutaneous (catheter-based) treatment

Short Title: Catheter-based Closure of the Patent Ductus

Manuscript Word Count: 990

Funding Source: C. Backes and J. Slaughter, Co-PIs (R01 HL145032-01)

Conflicts of Interest: Dr. Backes is a consultant for Abbott

Corresponding Author:

Carl Backes, MD

Nationwide Children's Hospital

700 Children's Drive

Columbus, OH 43205

e-mail: carl.backesjr@nationwidechildrens.org

Patent ductus arteriosus (PDA) is the most common cardiovascular abnormality during infancy, increases mortality risk 8-fold, and is linked to chronic lung disease, pulmonary hypertension, and congestive heart failure.¹ Early pharmacological treatment is commonly employed to close PDA in the first weeks of life, but 35-50% infants fail or have contraindications to drug therapy (failed early treatment). Considerable uncertainty exists regarding best treatment for the cohort of infants following failed early treatment who continue to have clinical and hemodynamic perturbations potentially attributable to the ductus.² Traditionally, surgery was used following failed early treatment, with some evidence, albeit limited, suggestive of lower mortality and improved outcomes following surgical closure.³ Over the past decade, associations between surgical PDA ligation and adverse outcomes within large cohort studies led to a secular trend away from definitive ductal closure.⁴

Currently, most health care providers have adopted an observational (non-intervention) approach to the PDA following failed early treatment. This approach avoids (or at least delays) procedure-related complications, but prolongs the duration of PDA exposure while the clinician watchfully waits for a spontaneous ductal closure. However, consensus on how long observation can be tried is lacking, with some evidence of greater risks following prolonged exposure.⁵ The American Academy of Pediatrics notes the urgent need for clinical trials to identify the optimal treatment strategy for this subgroup of infants, but lack of equipoise between the surgical and watchful waiting approaches' precluded the conduct of such trials.² In the absence of clear evidence, the fundamental question of whether closure versus non-closure of the ductus following failed early treatment improves important longer-term patient outcomes

remains unanswered. But what if there were an alternative, minimally-invasive approach to achieve definitive ductal closure? Might it lead to improved outcomes in infants deemed to be at high-risk for PDA-attributable complications?

On January, 11th, 2019, the US Food and Drug Administration approved the Amplatzer Piccolo™ Occluder (or Amplatzer duct occlude II additional sizes, or ADO-II AS).⁶ The device is designed for ductal closure among infants weighing >700 grams with a postnatal age ≥ 3 days. While the device has been available in Europe for over 5 years, U.S. health care providers now have this non-surgical alternative to achieve definitive PDA closure. Design and technique modifications are attractive, including less bulky retention disks, low profile delivery system via 4 French catheters, and device delivery by venous-only cannulation. Promising data on technical feasibility, short-term safety, and of potential short and longer-term improvements in respiratory status (days on mechanical ventilation, need for diuretic therapy) from single-center, observational studies, has led to growing interest in percutaneous closure among lower weight infants. In fact, catheter-based closure has surgery as the primary technique for definitive PDA closure among preterm infants at some U.S centers.⁷

While catheter-based PDA closure provides the neonatal community with an opportunity to advance our understanding of optimal treatment practices, lack of comparisons with alternative treatments (e.g. conservative therapy) obscures risk/benefit profiles, reinforcing the need for well-designed, multicenter, randomized controlled trials (RCTs). Prior to the design and execution of such trials, a number of barriers to study conduct and execution must be overcome. At present, deeply entrenched beliefs and biases regarding optimal PDA care exist. Many health care

providers lack sufficient equipoise to support the conduct of robust, clinical trials.

Liebowitz *et. al.* described that, in the PDA TOLERATE Trial, 152 potentially eligible infants were not recruited and received treatment of their PDA outside the trial due to lack of physician equipoise.⁸ In the absence of consensus on optimal treatment

practices, health care providers are encouraged to support patient enrollment into clinical studies.² Even if health care providers are willing to participate,

parents/caregivers may be reluctant to provide consent. Differences between enrolled versus eligible but not enrolled infants, limit the external validity of study findings.

Innovative qualitative research from adult studies has shown that clear and transparent discussions of the risks and benefits of treatment options, appropriately oriented to participants, can markedly increase consent rates in RCTs comparing intervention

versus non-intervention arms.⁹ Lack of formal training in the processes necessary to obtain parental consent, particularly for studies involving complex interventions among

high-risk patient populations, also contribute to low rates of study consent. Strategies to support health care providers to effectively present high quality information and

communicate successfully with adult patients have been developed,¹⁰ but would need adapting for pediatric trials. Novel trial designs, such as comprehensive-cohorts, that

incorporate parallel follow-up for caregivers who refuse randomization, can provide

valuable observational data on outcomes to increase generalizability. Finally, evidence

is growing on the importance of incorporating family-centered outcomes into proposed trials, with the goal of better understanding the impact these interventions have on

caregivers.

A number of considerations in the design of contemporary, pragmatic trials on PDA management are warranted. Infants who fail early treatment and continue to have clinical and hemodynamic sequelae potentially attributable to the ductus are at the crux of the medical debate. These infants, beyond the window when drug therapy is typically used and spontaneous closure has yet to occur, represent an ongoing therapeutic dilemma for health care providers. In trials incorporating catheter-based closure, prioritization of this high-risk subgroup is paramount. Second, previous PDA trials are limited because of high rates of open label treatments in control (non-intervention) groups. To adequately explore if differences in the duration of PDA exposure contribute to adverse outcomes, rescue criteria in the control arm of RCTs should be carefully designed so they are infrequently used and consistently applied.

The practice of catheter-based PDA closure among premature infants has not been adequately compared to alternative treatment strategies, leaving health care providers without evidence-based data to guide clinical decision making. This reinforces the need for a well-designed, RCT. New strategies to increase the quality and efficiency of clinical studies on PDA management must be considered. Without high-quality randomized studies, the debate of how best to care for infants following failed early treatment will continue and prevent progress in the field.

REFERENCES

1. Noori S, McCoy M, Friedlich P, Bright B, Gottipati V, Seri I, et al. Failure of ductus arteriosus closure is associated with increased mortality in preterm infants. *Pediatrics*. Jan 2009;123:e138-144.
2. Benitz WE, Committee on F, Newborn AAoP. Patent Ductus Arteriosus in Preterm Infants. *Pediatrics*. Jan 2016;137.
3. Cotton RB, Stahlman MT, Bender HW, Graham TP, Catterton WZ, Kovar I. Randomized trial of early closure of symptomatic patent ductus arteriosus in small preterm infants. *J Pediatr*. Oct 1978;93:647-651.
4. Kabra NS, Schmidt B, Roberts RS, Doyle LW, Papile L, Fanaroff A, et al. Neurosensory impairment after surgical closure of patent ductus arteriosus in extremely low birth weight infants: results from the Trial of Indomethacin Prophylaxis in Preterms. *J Pediatr*. Mar 2007;150:229-234, 234 e221.
5. Elhoff JJ, Ebeling M, Hulsey TC, Atz AM. Potential Unintended Consequences of a Conservative Management Strategy for Patent Ductus Arteriosus. *Congenit Heart Dis*. Jan-Feb 2016;11:52-57.
6. Administration TUFaD. Premarket Approval (PMA) of the AMPLATZER Piccolo Occluder. In: Administration TUFaD, ed2019.
7. Zahn EM, Peck D, Phillips A, Nevin P, Basaker K, Simmons C, et al. Transcatheter Closure of Patent Ductus Arteriosus in Extremely Premature Newborns: Early Results and Midterm Follow-Up. *JACC Cardiovasc Interv*. Dec 12 2016;9:2429-2437.
8. Liebowitz M, Katheria A, Sauberan J, Singh J, Nelson K, Hassinger DC, et al. Lack of Equipoise in the PDA-TOLERATE Trial: A Comparison of Eligible Infants Enrolled in the Trial and Those Treated Outside the Trial. *J Pediatr*. Jun 26 2019.
9. Donovan JL, Lane JA, Peters TJ, Brindle L, Salter E, Gillatt D, et al. Development of a complex intervention improved randomization and informed consent in a randomized controlled trial. *J Clin Epidemiol*. Jan 2009;62:29-36.
10. Mills N, Gaunt D, Blazeby JM, Elliott D, Husbands S, Holding P, et al. Training health professionals to recruit into challenging randomized controlled trials improved confidence: the development of the QuinteT randomized controlled trial recruitment training intervention. *J Clin Epidemiol*. Mar 2018;95:34-44.